# ZNF630

## Overview
ZNF630 is a gene that encodes the zinc finger protein 630, which is part of the KRAB domain-containing zinc finger proteins (KRAB-ZFPs) family. These proteins are characterized by their role in transcriptional regulation, primarily functioning as transcriptional repressors. Zinc finger protein 630 is implicated in various cellular processes, including cell cycle regulation, differentiation, and apoptosis, and is involved in imprinting the genome with site-specific DNA methylation during early embryogenesis (Rashid2020Proteomic). The gene is expressed in the adult brain and during fetal development, suggesting a potential role in cognitive function, although its specific functions in healthy human cells are not fully elucidated (Lugtenberg2010Recurrent). ZNF630 has also been studied in the context of reproductive health, with alterations in its expression linked to conditions such as polycystic ovary syndrome (PCOS) and infertility (Rashid2020Proteomic). Despite these associations, the precise molecular mechanisms and clinical significance of ZNF630 remain areas of active research.

## Function
ZNF630, a member of the zinc finger protein family, is involved in transcriptional regulation, acting as a transcriptional repressor. It is part of the KRAB domain-containing zinc finger proteins (KRAB-ZFPs), which are known to play roles in various cellular processes, including cell cycle regulation, cell proliferation, differentiation, and apoptotic processes (Rashid2020Proteomic). These proteins are also implicated in imprinting the genome with site-specific DNA methylation during early embryogenesis, which is maintained throughout development. ZNF630 is expressed in the adult brain and during fetal development, suggesting a potential role in cognitive function, although its specific function in healthy human cells is not fully detailed (Lugtenberg2010Recurrent).

In the context of polycystic ovary syndrome (PCOS), ZNF630 has been found to be downregulated in infertile PCOS subjects, indicating a potential role in fertility and endometrial receptivity (Rashid2020Proteomic). However, the precise molecular activities and cellular locations of ZNF630 in healthy human cells remain unclear, as the available studies primarily focus on its expression changes in disease contexts.

## Clinical Significance
ZNF630 has been investigated for its potential clinical significance in various conditions, although its role remains unclear. Studies have shown that deletions and duplications of the ZNF630 gene occur in both individuals with mental retardation (MR) and healthy controls, suggesting that these genetic variations are not exclusively associated with MR (Lugtenberg2010Recurrent). Despite a higher frequency of ZNF630 deletions in males with MR compared to controls, this difference was not statistically significant, indicating that ZNF630 deletions do not have a significant clinical impact on MR (Lugtenberg2010Recurrent).

In the context of infertility, a ~90 kb deletion encompassing ZNF630 was detected in cases of spermatogenic failure, including non-obstructive azoospermia and severe oligozoospermia. However, the prevalence of this deletion in the general population suggests it is unlikely to be a major contributor to spermatogenic failure (Kikas2023Microdeletions). Additionally, ZNF630 was found to be downregulated in women with polycystic ovary syndrome (PCOS) and infertility, indicating a potential role in fertility issues (Rashid2020Proteomic). Despite these associations, the clinical significance of ZNF630 in these conditions requires further investigation.

## Interactions



## References


[1. (Rashid2020Proteomic) Nadia Rashid, Aruna Nigam, S.K. Jain, Samar Husain Naqvi, and Saima Wajid. Proteomic sift through serum and endometrium profiles unraveled signature proteins associated with subdued fertility and dampened endometrial receptivity in women with polycystic ovary syndrome. Cell and Tissue Research, 380(3):593–614, January 2020. URL: http://dx.doi.org/10.1007/s00441-020-03171-3, doi:10.1007/s00441-020-03171-3. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s00441-020-03171-3)

[2. (Lugtenberg2010Recurrent) Dorien Lugtenberg, Luiz Zangrande‐Vieira, Maria Kirchhoff, Annabel C. Whibley, Astrid R. Oudakker, Susanne Kjaergaard, Angela M. Vianna‐Morgante, Tjitske Kleefstra, Mariken Ruiter, Fernanda S. Jehee, Reinhard Ullmann, Charles E. Schwartz, Michael Stratton, F. Lucy Raymond, Joris A. Veltman, Terry Vrijenhoek, Rolph Pfundt, Janneke H.M. Schuurs‐Hoeijmakers, Jayne Y. Hehir‐Kwa, Guy Froyen, Jamel Chelly, Hans Hilger Ropers, Claude Moraine, Jozef Gècz, Jeroen Knijnenburg, Sarina G. Kant, Ben C.J. Hamel, Carla Rosenberg, Hans van Bokhoven, and Arjan P.M. de Brouwer. Recurrent deletion of znf630 at xp11.23 is not associated with mental retardation. American Journal of Medical Genetics Part A, 152A(3):638–645, February 2010. URL: http://dx.doi.org/10.1002/ajmg.a.33292, doi:10.1002/ajmg.a.33292. This article has 5 citations.](https://doi.org/10.1002/ajmg.a.33292)

[3. (Kikas2023Microdeletions) Triin Kikas, Anna Maria Punab, Laura Kasak, Olev Poolamets, Vladimir Vihljajev, Kristjan Pomm, Mario Reiman, Stanislav Tjagur, Paul Korrovits, Margus Punab, and Maris Laan. Microdeletions and microduplications linked to severe congenital disorders in infertile men. Scientific Reports, January 2023. URL: http://dx.doi.org/10.1038/s41598-023-27750-w, doi:10.1038/s41598-023-27750-w. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-023-27750-w)